Daniel Arias: Good morning, guys. Thanks for the question. So Rob, maybe just a follow-up on your new versus existing customer comment there. When you think about the sales funnel that will translate to orders and revenue next year, how does the mix look when it comes to placement at those new accounts versus repeat purchases? And then as a follow-up to that, on the cell and gene therapy side, you sound kind of positive there. Can you just talk about how those conversations are going? Obviously, there are some ups and downs with some of those companies and the things that they’re experiencing these days and just the spending level that you might expect there. So how does visibility compare there to the other parts of the market?
Robert Spignesi: Yes, Dan, thanks for the question. So with regard to new versus existing, it’s balanced. We — it’s weighted towards existing customers, as you may imagine, and you heard we brought a new one on. So as we continue to chip away at some of the larger customers out there, our funnel, our outlook and our funnel is weighted in that direction given our land and expand strategy. That being said, again, as with the full team out there across North America, Europe and Asia, we are generating new opportunities kind of across our segments that include both new and existing. So we like the way our funnel looks with regard to both new and existing. And as I mentioned, from the — excited about what we’re hearing and seeing with some of our larger customers and getting better insight into their rollout plans and budgets against those.
On the cell therapy front, I think you heard with regard to CAR-T in particular, or cell and gene generally in CAR-T in particular, we’ve done well there. Our value proposition resonates quite well. So I think it’s a situation where our particular technology fits their manufacturing needs quite well, and it’s really the — and in our view, the only real fully automated system that can serve their needs. More broadly in cell and gene therapy, we are active with CDMOs who operate in that space that the CMO business is healthy as well as, obviously, the broader ecosystem with [indiscernible] manufacturers and other who continue to be healthy as well. So we’re obviously watching it. We’re strong in the space broadly. And — but as I mentioned on the call as well, we’ve got a good footprint in biologics manufacturing, which is our largest segment and small molecule as well.
So we watch our segment mix carefully. And while we’re strong in cell and gene therapy, it certainly isn’t the only segment that we’re focused on. And again, it’s important to note that biologics is our largest segment.
Daniel Arias: Yes. Got you. Okay. And then Sean, on consumables how do you think pull-through tracks on an annualized per system base meant into year-end? And then can you just touch on why consumables will be down next quarter, I think that’s actually two sequential down quarters. It seems like you feel pretty good about momentum. So maybe just touch on how consumables [indiscernible] over the next one to two quarters.
Sean Wirtjes: Sure. Yes. So I didn’t break it down, we still expect to grow single digits in year-over-year pull-through effectively when we look at the full year. I think — do we get to high single digits. We may — we have a few headwinds that may keep us from getting quite to where we thought we’d get to a couple of quarters ago, but it’s mainly due to timing. So if you kind of break down Q3 and Q4, Q3 a couple of things working against us in terms of year-over-year growth. One is that we had some — a couple of hundred thousand dollars-worth of shipments pushed from Q2 to Q3 last year. And with our record quarter last quarter, we pulled probably a somewhat similar amount from Q3 this year into Q2 this year. So that comp is challenged both directions as a result of that.
